Long-Term Impact of Mild Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement
JACC: Cardiovascular Interventions · 2026
DOI: 10.1016/j.jcin.2025.09.004 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026. Verfasst von Yusuke Watanabe und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan. Electronic address: https://twitter.com/Yusukeewatanab. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Insufficiency, Aortic Valve, Aortic Valve Stenosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Edwards Lifesciences Corporation, Medtronic Inc, Abbott Vascular.
Abstract (Originalsprache)
BACKGROUND: The clinical significance of mild paravalvular regurgitation (PVR) after transcatheter aortic valve replacement (TAVR) remains uncertain. OBJECTIVES: The aim of this study was to evaluate the impact of mild PVR on long-term clinical outcomes and bioprosthetic valve failure (BVF) following TAVR. METHODS: A total of 5,068 patients from the OCEAN-TAVI (Optimized Catheter Valvular Intervention-Transcatheter Aortic Valve Implantation; UMIN000020423) registry who underwent TAVR and had no or trace or mild PVR at discharge were analyzed. Patients were stratified according to PVR severity and followed for up to 9 years. The primary outcomes were all-cause mortality and BVF, defined according to Valve Academic Research Consortium 3 criteria. RESULTS: Median follow-up duration was 4.7 years (Q1-Q3: 2.9-6.0 years). Mild PVR was observed in 1,601 patients (31.6%). At 9-year follow-up, Kaplan-Meier analysis demonstrated a significantly higher cumulative incidence of all-cause mortality (75.9% [95% CI: 71.3%-80.2%] vs 72.2% [95% CI: 68.1%-76.3%]; log-rank P = 0.014) and BVF (20.7% [95% CI: 12.8%-32.5%] vs 17.3% [95% CI: 11.0%-26.6%]; P = 0.029) in patients with mild PVR than in those with no or trace PVR. Fine-Gray analysis confirmed mild PVR as an independent predictor of BVF (subdistribution HR [sHR]: 1.48; 95% CI: 1.07-2.04; P = 0.018), and Cox regression showed a significant association with all-cause mortality (HR: 1.11; 95% CI: 1.02-1.21; P = 0.014). The risk for BVF was especially elevated in patients receiving balloon-expandable valves (sHR: 1.46; 95% CI: 1.02-2.08; P = 0.038), those undergoing nontransfemoral TAVR (sHR: 5.58; 95% CI: 1.57-19.9; P = 0.0086), and those with impaired renal function (estimated glomerular filtration rate < 30 mL/min/1.73 m2; sHR: 3.86; 95% CI: 1.30-11.5; P = 0.015). Baseline mild PVR was independently associated with an increased risk for progression to moderate or greater PVR (HR: 3.74; 95% CI: 2.84-4.92; P < 0.001). CONCLUSIONS: Mild PVR after TAVR is associated with a significantly increased risk for BVF and all-cause mortality, highlighting the importance of optimizing valve deployment and monitoring patients with even mild PVR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan. Electronic address: https://twitter.com/Yusukeewatanab.
- Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan; Department of Cardiology, Nagoya Heart Center, Nagoya, Japan; Department of Cardiology, Gifu Heart Center, Gifu, Japan.
- Department of Cardiology, IMS Tokyo Katsushika General Hospital, Tokyo, Japan.
- Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
- Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan.
- Department of Cardiology, New Tokyo Hospital, Matsudo, Japan.
Förderung
- Edwards Lifesciences Corporation
- Medtronic Inc
- Abbott Vascular
- Boston Scientific Corporation
- Daiichi Sankyo Company Limited
Zitieren
APA
Watanabe, Y., Yamamoto, M., Hioki, H., Saito, M., Omiya, J., Kito, K., Iseki, Y., Arakawa, M., Miura, M., Shirai, S., Ishizu, K., Naganuma, T., Yamanaka, F., Noguchi, M., Ohno, Y., Shimura, T., Yashima, F., Takagi, K., Nakazawa, G., …, & OCEAN-TAVI Investigators (2026). Long-Term Impact of Mild Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.09.004
Vancouver
Watanabe Y, Yamamoto M, Hioki H, Saito M, Omiya J, Kito K, et al. Long-Term Impact of Mild Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2025.09.004
BibTeX
@article{Watanabe2026,
author = {Watanabe, Yusuke and Yamamoto, Masanori and Hioki, Hirofumi and Saito, Masafumi and Omiya, Jo and Kito, Kento and Iseki, Yosei and Arakawa, Masataka and Miura, Mizuki and Shirai, Shinichi and Ishizu, Kenichi and Naganuma, Toru and Yamanaka, Futoshi and Noguchi, Masahiko and Ohno, Yohei and Shimura, Tetsuro and Yashima, Fumiaki and Takagi, Kensuke and Nakazawa, Gaku and Asami, Masahiko and Izumo, Masaki and Nishina, Hidetaka and Fuku, Yasushi and Otsuka, Toshiaki and Hayashida, Kentaro and OCEAN-TAVI Investigators, OCEAN-TAVI Investigators},
title = {Long-Term Impact of Mild Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
doi = {10.1016/j.jcin.2025.09.004}
}
EUVIMED